A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus

  • A. Avogaro, A. Giaccari, P. Fioretto, S. Genovese, F. Purrello, F. Giorgino, S. Del Prato
  • Expert Review of Clinical Pharmacology, May 2017, Taylor & Francis
  • DOI: 10.1080/17512433.2017.1322507

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1080/17512433.2017.1322507

The following have contributed to this page: Andrea Giaccari